Cell source determines the immunological impact of biomimetic nanoparticles

Simple item page
dc.creatorChristian Boada
dc.date2016
dc.date.accessioned2018-10-18T20:34:58Z
dc.date.available2018-10-18T20:34:58Z
dc.descriptionRecently, engineering the surface of nanotherapeutics with biologics to provide them with superior biocompatibility and targeting towards pathological tissues has gained significant popularity. Although the functionalization of drug delivery vectors with cellular materials has been shown to provide synthetic particles with unique biological properties, these approaches may have undesirable immunological repercussions upon systemic administration. Herein, we comparatively analyzed unmodified multistage nanovectors and particles functionalized with murine and human leukocyte cellular membrane, dubbed Leukolike Vectors (LLV), and the immunological effects that may arise in vitro and in vivo. Previously, LLV demonstrated an avoidance of opsonization and phagocytosis, in addition to superior targeting of inflammation and prolonged circulation. In this work, we performed a comprehensive evaluation of the importance of the source of cellular membrane in increasing their systemic tolerance and minimizing an inflammatory response. Time-lapse microscopy revealed LLV developed using a cellular coating derived from a murine (i.e., syngeneic) source resulted in an active avoidance of uptake by macrophage cells. Additionally, LLV composed of a murine membrane were found to have decreased uptake in the liver with no significant effect on hepatic function. As biomimicry continues to develop, this work demonstrates the necessity to consider the source of biological material in the development of future drug delivery carriers. © 2015.
dc.identifier.doi10.1016/j.biomaterials.2015.11.054
dc.identifier.endpage177
dc.identifier.issn1429612
dc.identifier.startpage168
dc.identifier.urihttp://hdl.handle.net/11285/630405
dc.identifier.volume82
dc.languageeng
dc.publisherElsevier Ltd
dc.relationhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84957595368&doi=10.1016%2fj.biomaterials.2015.11.054&partnerID=40&md5=3699c68eca0e9c62b8a18ec47a9e1935
dc.relationInvestigadores
dc.relationEstudiantes
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceBiomaterials
dc.subjectAntigen-antibody reactions
dc.subjectBiocompatibility
dc.subjectBiomimetics
dc.subjectCell membranes
dc.subjectDrug delivery
dc.subjectDrug products
dc.subjectImmunology
dc.subjectNanoparticles
dc.subjectBiomimetic nanoparticles
dc.subjectBiomimicry
dc.subjectComprehensive evaluation
dc.subjectImmunobiology
dc.subjectImmunological effects
dc.subjectNanovector
dc.subjectSystemic administration
dc.subjectTime-lapse microscopy
dc.subjectBiological materials
dc.subjectalanine aminotransferase
dc.subjectaspartate aminotransferase
dc.subjectbiomimetic material
dc.subjectcreatinine
dc.subjectgamma interferon
dc.subjectinterleukin 10
dc.subjectinterleukin 12
dc.subjectinterleukin 1alpha
dc.subjectinterleukin 1beta
dc.subjectinterleukin 2
dc.subjectinterleukin 3
dc.subjectinterleukin 6
dc.subjectleukolike vector
dc.subjectmultistage nanovector
dc.subjectnanocarrier
dc.subjectnanoparticle
dc.subjectreactive oxygen metabolite
dc.subjecttranscription factor RelA
dc.subjecttumor necrosis factor alpha
dc.subjectunclassified drug
dc.subjectbiomaterial
dc.subjectbiomimetic material
dc.subjectnanocapsule
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectbiocompatibility
dc.subjectcell interaction
dc.subjectcontrolled study
dc.subjectcytokine release
dc.subjectdrug delivery system
dc.subjecthuman
dc.subjecthuman cell
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectinternalization
dc.subjectleukocyte membrane
dc.subjectliver function
dc.subjectmacrophage
dc.subjectmononuclear phagocyte
dc.subjectmouse
dc.subjectnonhuman
dc.subjectopsonization
dc.subjectphagocytosis
dc.subjectpriority journal
dc.subjectprotein expression
dc.subjectstatic electricity
dc.subjectsurface charge
dc.subjecttime lapse imaging
dc.subjectzeta potential
dc.subjectanimal
dc.subjectBagg albino mouse
dc.subjectcell culture
dc.subjectcomparative study
dc.subjectdrug effects
dc.subjectevaluation study
dc.subjectimmunology
dc.subjectinnate immunity
dc.subjectleukocyte
dc.subjectAnimals
dc.subjectBiocompatible Materials
dc.subjectBiomimetic Materials
dc.subjectCells, Cultured
dc.subjectImmunity, Innate
dc.subjectLeukocytes
dc.subjectMice
dc.subjectMice, Inbred BALB C
dc.subjectNanocapsules
dc.subject.classification7 INGENIERÍA Y TECNOLOGÍA
dc.titleCell source determines the immunological impact of biomimetic nanoparticles
dc.typeArtículo
refterms.dateFOA2018-10-18T20:34:58Z

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
84957595368.pdf
Size:
47.21 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Download

Collections

Artículo
logo

El usuario tiene la obligación de utilizar los servicios y contenidos proporcionados por la Universidad, en particular, los impresos y recursos electrónicos, de conformidad con la legislación vigente y los principios de buena fe y en general usos aceptados, sin contravenir con su realización el orden público, especialmente, en el caso en que, para el adecuado desempeño de su actividad, necesita reproducir, distribuir, comunicar y/o poner a disposición, fragmentos de obras impresas o susceptibles de estar en formato analógico o digital, ya sea en soporte papel o electrónico. Ley 23/2006, de 7 de julio, por la que se modifica el texto revisado de la Ley de Propiedad Intelectual, aprobado

DSpace software copyright © 2002-2026

Licencia